Lessons Learned from Protective Immune Responses to Optimize Vaccines Against Cryptosporidiosis
Overview
Affiliations
In developing countries, cryptosporidiosis causes moderate-to-severe diarrhea and kills thousands of infants and toddlers annually. Drinking and recreational water contaminated with spp. oocysts has led to waterborne outbreaks in developed countries. A competent immune system is necessary to clear this parasitic infection. A better understanding of the immune responses required to prevent or limit infection by this protozoan parasite is the cornerstone of development of an effective vaccine. In this light, lessons learned from previously developed vaccines against spp. are at the foundation for development of better next-generation vaccines. In this review, we summarize the immune responses elicited by naturally and experimentally-induced spp. infection and by several experimental vaccines in various animal models. Our aim is to increase awareness about the immune responses that underlie protection against cryptosporidiosis and to encourage promotion of these immune responses as a key strategy for vaccine development. Innate and mucosal immunity will be addressed as well as adaptive immunity, with an emphasis on the balance between T1/T2 immune responses. Development of more effective vaccines against cryptosporidiosis is needed to prevent spp.-related deaths in infants and toddlers in developing countries.
Mira A, Garro C, de Alba P, Monti D, Lang M, Vivas A Vaccines (Basel). 2025; 13(2).
PMID: 40006709 PMC: 11860195. DOI: 10.3390/vaccines13020162.
Gut Barrier Dysfunction and Microbiota Variations in Cryptosporidiosis: A Comprehensive Review.
Ali M, Xu C, Wang M, Hina Q, Ji Y, Anwar S Vet Sci. 2025; 12(2).
PMID: 40005845 PMC: 11861801. DOI: 10.3390/vetsci12020085.
Cryptosporidiosis outbreaks linked to the public water supply in a military camp, France.
Watier-Grillot S, Costa D, Petit C, Razakandrainibe R, Larreche S, Tong C PLoS Negl Trop Dis. 2022; 16(9):e0010776.
PMID: 36095017 PMC: 9499286. DOI: 10.1371/journal.pntd.0010776.
Controlled Human Infection Models To Accelerate Vaccine Development.
Choy R, Louis Bourgeois A, Ockenhouse C, Walker R, Sheets R, Flores J Clin Microbiol Rev. 2022; 35(3):e0000821.
PMID: 35862754 PMC: 9491212. DOI: 10.1128/cmr.00008-21.
Gallego-Lopez G, Mendoza Cavazos C, Tibabuzo Perdomo A, Garfoot A, OConnor R, Knoll L Infect Immun. 2021; 90(2):e0063821.
PMID: 34928716 PMC: 8852703. DOI: 10.1128/iai.00638-21.